Eosinophil Cationic Protein Concentrations among Crop and Dairy Farmers with Asthma by Stoleski, Saso et al.
  
_______________________________________________________________________________________________________________________________ 
456                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2018 Mar 15; 6(3):456-462. 
https://doi.org/10.3889/oamjms.2018.113 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Eosinophil Cationic Protein Concentrations among Crop and 
Dairy Farmers with Asthma 
 
 
Saso Stoleski
*
, Jordan Minov, Jovanka Karadzinska-Bislimovska, Dragan Mijakoski, Aneta Atanasovska 
 
Institute for Occupational Health of Republic of Macedonia - Skopje, WHO Collaborating Center, Ga
2
len Collaborating 
Center, Skopje, Republic of Macedonia 
 
Citation: Stoleski S, Minov J, Karadzinska- Bislimovska 
J, Mijakoski D, Atanasovska A. Eosinophil Cationic 
Protein Concentrations among Crop and Dairy Farmers 
with Asthma. Open Access Maced J Med Sci. 2018 Mar 
15; 6(3):456-462. 
https://doi.org/10.3889/oamjms.2018.113 
Keywords: Airway inflammation; Asthma; Farmers; 
Respiratory symptoms 
*Correspondence: Saso Stoleski. Institute for 
Occupational Health of R. Macedonia - Skopje, WHO 
Collaborating Center, Ga2len Collaborating Center, 
Skopje, Republic of Macedonia. E-mail: 
sstoleski@yahoo.com 
Received: 16-Jan-2018; Revised: 02-Feb-2018; 
Accepted: 20-Feb-2018; Online first: 21-Feb-2018 
Copyright: © 2018 Saso Stoleski, Jordan Minov, Jovanka 
Karadzinska-Bislimovska, Dragan Mijakoski, Aneta 
Atanasovska. This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
 
 
Abstract  
OBJECTIVE: To assess the mean serum eosinophil cationic protein (s-ECP) concentrations among crop and 
dairy farmers and office controls, and further examine its relation to exposure duration, smoking habit, as well as 
presence or absence of asthma. 
METHODS: A cross-sectional survey was performed including examined group (EG), composed by agricultural 
workers (87 crop - EG1 and 83 dairy farmers - EG2), and control group (CG) composed by 80 office workers 
within the same enterprise.  We have used a questionnaire to record the chronic respiratory symptoms, detailed 
work history, specific farming activities and tasks performed and smoking history. Evaluation of examined subjects 
also included lung function tests, diagnosis of asthma, and measurement of s-ECP as a marker of inflammation. 
RESULTS: The main finding of the present study is that s-ECP concentrations were raised in subjects with 
asthma independent of the smoking habit. The mean s-ECP concentrations were higher in subjects of EG1 and 
EG2 compared with those in CG, but without reaching statistical significance. Mean s-ECP concentrations were 
significantly higher among subjects in EG1 exposed more than 20 years, while mean s-ECP concentrations were 
non-significantly higher in subjects of EG2 exposed more than 20 years, compared to those exposed less than 20 
years. Mean s-ECP concentrations were higher among smokers within all three groups, but without reaching 
statistical significance between smokers and non-smokers. Mean s-ECP concentrations were significantly higher 
in subjects with asthma within EG1 (P = 0.049) and EG2 (P = 0.040), but also within those in CG (P = 0.046). 
CONCLUSION: Data obtained suggest that airway inflammation is present in farmers with asthma, and s-ECP is 
an important biomarker in means of reflecting disease severity and prognosis among exposed workers. 
 
 
 
 
 
 
 
Introduction 
 
Asthma is a chronic inflammatory disease of 
the airways in which many inflammatory cells have 
been found to play a role, particularly mast cells, 
eosinophils and T-lymphocytes. The association 
between eosinophilia and asthma was observed 
shortly after eosinophils were discovered. In patients 
with asthma, eosinophils are present in increased 
numbers in the blood, sputum and bronchoalveolar 
lavage fluid [1]. 
After activation, eosinophils can release 
granulocyte-derived proteins, the most toxic of which 
are eosinophil cationic protein (ECP) and major basic 
protein (MBP) [2]. Clinical research has suggested 
emerging clinical usefulness of eosinophil granule 
proteins as serological markers in the assessment 
and management of asthma, of which ECP has been 
most widely characterised and researched. The 
results of many studies indicate that the degree of 
eosinophilic expression, that is, the levels of ECP in 
the blood and serum correlate with the degree of 
asthma severity and the extent of the achieved 
asthma control [3].  
Immunologically potent substances such as 
antigens, endotoxins, glucans and substances with 
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complement-stimulating and adjuvant effect have 
been identified in the agricultural dust, exposure to 
which may provoke inflammatory reactions in the 
airways [4]. In a population study of farmers, lifetime 
cumulative prevalence of asthma was 6.3%, and for 
current asthma was 3.1%. Melbostad et al. found that 
animal production (husbandry) and familial 
predisposition interact as risk factors for asthma in 
farmers, and that atopy and specific allergies to cow, 
swine, grass and mites (D. pteronyssinus, L. 
destructor and T. putrescentiae) are associated with 
asthma and work-related upper and lower airway 
symptoms [5]. Eosinophil airway inflammation is 
characteristic of asthma, and, as shown in provocation 
studies, seems to be related to current asthma activity 
and recent allergen exposure [6]. Serum ECP value is 
a relevant marker of current eosinophil inflammatory 
activity in asthma [7]. There is a need for markers of 
airway inflammation in epidemiological studies of 
asthma. 
In an epidemiological study of asthma in 
Norwegian farmers, Melbostad et al. [8] investigated 
s-ECP values in cases of atopic and non-atopic 
asthma, respectively, and in a control group without 
asthma and atopy. They also studied the relationship 
between airway obstruction, as an indicator of asthma 
activity, and s-ECP values, and whether ECP values 
were related to some positive allergen tests and 
specific allergies in asthmatic farmers. 
Activated eosinophils in the asthmatic release 
their granular proteins, supporting the view that they 
have a pro-inflammatory role in the development of 
airway narrowing in asthma [9]. One such protein, 
ECP, was detected in bronchial biopsies and 
measured BAL [10], sputum and peripheral blood [11]. 
Serum and sputum ECP levels have been found to be 
correlated with the severity of asthma and allergen 
exposure [12]. It has been found that ECP can be 
used to monitor asthma inflammation [13]. 
The Italian study conducted among asthmatic 
grass-sensitized farmers by Di Gioacchino et al. [14] 
demonstrates that in grass sensitized farmers with 
asthmatic symptoms occurring for several weeks after 
grass pollination has ceased, the degree of airway 
hyperresponsiveness and the duration of post 
seasonal symptoms are directly related to the 
increase of ECP levels during the pollen season, as 
well as to the level of total IgE in serum. This allows 
identification of two candidate biomarkers (easily 
usable in routine clinical practice) for the risk of 
developing prolonged asthma symptoms, and for the 
effective monitoring of anti-inflammatory treatment 
and allergen-specific immunotherapy. The review of 
the literature indicated that s-ECP might serve as an 
objective indicator for clinical activity in asthma, and 
point to a possible pathophysiological axis in asthma 
that is based upon altered airway resistance due to 
eosinophils and eosinophil activity markers [15]. 
In the actual study we have assessed the 
mean s-ECP concentrations among crop and dairy 
farmers and office controls, and further examined its 
relation to exposure duration, smoking habit, as well 
as the presence or absence of asthma. 
 
 
Subjects and Methods 
 
Study design and setting 
We have performed cross-sectional research 
in the Center for Respiratory Functional Diagnostics at 
the Institute for Occupational Health of Republic of 
Macedonia, Skopje - WHO Collaborating Center for 
Occupational Health and GA
2
LEN Collaborating 
Center within the period September 2014 and April 
2015. The examined and control groups are the same 
cohorts that were used in our previous study [16].                                                                                                                          
 
Subjects 
The survey included workers employed at 
agricultural enterprise divided into two groups: 
examined group (EG), composed by agricultural 
workers (crop and dairy farmers), and control group 
(CG) composed by office workers within the same 
enterprise.  
EG consists of 170 subjects, while CG has 80 
examinees. For the study purposes, and depending 
on the main agricultural activity, subjects were divided 
into two groups, examined group 1 (EG1) and 
examined group 2 (EG2). EG1 comprised 87 crop 
farmers (mean age = 53.4 ± 7.8 years) engaged in 
crop farming (mean duration of exposure 22.9 ± 7.8 
years) with main activities composed of cultivating 
crops and vegetables, planting, digging, use of 
mechanised equipment, irrigation, and pesticide 
handling. They were exposed to various respiratory 
agents: dust, inappropriate climate, fumes, vapours 
and pesticides. EG2 consists of 83 dairy farmers 
(mean age = 52.6  8.7 years) employed as dairy 
farmers (mean duration of exposure 23.7  7.6 years), 
working inside confinement buildings, and exposed to: 
dust, inappropriate microclimate conditions, chemical 
hazards, vapors, gases, heavy manual work, animal 
contact, unfavorable body positions, and repetitive 
hand movements. Their main occupational activities 
were: preparation of fodder feeding and animal meals, 
milking, staying in the barn, preparation of straw, and 
haymaking, cattle raising, as well as taking care about 
milk hygiene and animal health.  
Also, a similar group of 80 office workers 
(mean age = 52.7  8.2 years) with no exposure to 
respiratory agents, matched for age, duration of 
employment, daily smoking and socioeconomic status 
was studied as a control.  
The Institute’s ethics committee has approved 
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the content of our study protocol, whereas each 
examined subject was informed and gave written 
consent before any involvement in the study. 
 
Questionnaire 
All study subjects were interviewed by the 
standardised questionnaire, including questions on 
work history, respiratory symptoms in the last 12 
months, and smoking habit.  
Chronic respiratory symptoms in the last 12 
months (a cough, phlegm, dyspnea, wheezing, and 
chest tightness) were obtained using the European 
Community for Coal and Steel questionnaire (ECCS -
87), and the European Community Respiratory Health 
Survey (ECRHS) questionnaire [17] [18]. 
Classification of smoking status was done according 
to the World Health Organization (WHO) guidelines on 
definitions of smoking status [19]. 
Daily smoker was defined as a subject who 
smoked at the time of the field survey at least once a 
day, except on days of religious fasting. Among daily 
smokers, lifetime cigarette smoking and the daily 
mean of cigarettes smoked were also assessed. 
Pack-years smoked were calculated according to the 
actual recommendations [20]. Ex-smoker was defined 
as a formerly daily smoker, no longer smokes. 
Passive smoking or exposure to environmental 
tobacco smoke (ETS) was defined as the exposure of 
a person to tobacco combustion products from 
smoking by others [21]. 
 
Spirometry 
All study subjects underwent spirometry 
testing, performed by spirometer Ganshorn 
SanoScope LF8 (Ganshorn Medizin Electronic GmbH, 
Germany), measuring forced vital capacity (FVC), 
forced expiratory volume in one second (FEV1), 
FEV1/FVC ratio, and maximal expiratory flow at 50%, 
75%, and 25–75% of FVC (MEF50, MEF75, and MEF25-
75, respectively), by recording the best result from 
three measurements of the values of FEV1 within 5 % 
of each other. The results were expressed as 
percentages of the predicted values according to the 
European Community for Coal and Steel (ECCS) 
norms [22]. 
 
Diagnostic criteria for asthma 
According to the actual recommendations by 
Global Initiative for Asthma (GINA) asthma in subjects 
with normal spirometric findings is defined as 
symptomatic bronchial hyperresponsiveness (BHR) 
with PC20 ≤ 4 mg/mL, while in those with lower values 
of spirometric parameters as a positive bronchodilator 
test [23].    
 
Measurement of s-ECP concentrations as 
markers of inflammation 
Mean s-ECP concentrations are measured by 
chemiluminescent immunoassay method with 
Immulite 1000 in subjects with chronic respiratory 
symptoms and spirometric impairment. s-ECP 
concentrations < 24 µg/L are within the normal range 
[24].  
 
Statistical analysis 
We have analysed the data using Statistica 
for Windows version 7. Continuous variables were 
expressed as mean values with standard deviation 
and categorical variables as numbers and 
percentages. The comparison of mean ЕCP serum 
concentrations was performed by independent-
samples T-test. A P-value of less than 0.05 was 
considered statistically significant. 
 
 
Results 
 
Table 1 gives an overview of the demographic 
and overall characteristics of the subjects within the 
examined and control groups. 
Table 1: Demographic and overall characteristics of the study 
subjects 
Variable EG1 (n = 87) EG2 (n = 83) CG (n = 80) 
Gender/М/F ratio 3.6 2.6 2.7 
Age/years 53.4  7.8 52.6  8.7 52.7  8.2 
BMI/ kg m
-2
 25.1  3.5 25.4  3.6 26.2  3.7 
Duration of employment / years 29.2  8.9 26.3  10.1 25.3  9.8 
Exposure duration / years 22.9  7.8 23.7  7.6 / 
Active (daily) smokers 45 (51.7%) 39 (46.9%) 39 (48.7%) 
Smoking experience/years 19.7  8.1 18.9  7.6 19.2  7.8 
Cigarettes / day 15.4  7.3 14.6  6.8 14.8 ± 7.2 
Ex-smokers 12 (13.8%) 9 (10.8%) 12 (15%) 
Passive smokers 11 (12.6%) 8 (9.6%) 7 (8.7%) 
Numerical data are expressed as mean values with standard deviations; frequencies of 
active, passive, and ex-smokers are given as number and percent of subjects with certain 
variable.М: males; F: females; BMI: body mass index. 
 
Table 2 shows the frequencies of asthma 
symptoms (a cough, dyspnea, wheezing and/or chest 
tightness), positive BD tests, positive non-specific 
histamine challenge tests with PC20  4 mg / mL, as 
well as asthma detected among subjects in EG1, EG2 
and CG. 
Table 2: Frequency of asthma symptoms, positive BD tests, 
positive histamine challenge tests with PC20  4 mg/mL, and 
asthma among subjects in EG1, EG2 and CG 
Variable EG1 (n = 87) EG2 (n = 83) CG (n = 80) 
Respiratory symptoms in the 
last 12 months 
26 (29.9%) 24 (28.9%) 16 (20%) 
Positive BD test 15 (17.2%) 14 (16.9%) 8 (10%) 
Positive histamine challenge 
test with PC204 mg/mL 
9 (10.3%) 7 (8.5%) 5 (6.3%) 
Asthma 7 (8%) 6 (7.2%) 4 (5%) 
Data are given as number and percent of subjects with a certain variable. 
 
For the study purposes, we have examined 
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the marker of chronic eosinophil inflammatory activity-
s-ECP among subjects in the three groups having one 
or more chronic respiratory symptoms and / or 
spirometric impairments. 
 
Determination of mean s-ЕCP 
concentrations 
The mean s-ECP concentrations were higher 
in EG1 compared to CG, but without statistical 
significance (Table 3). 
Table 3: Mean s-ECP concentrations in subjects of EG1 and CG 
 EG1 
(n = 35) 
CG 
(n = 15) 
P-value* 
    
s-ECP (µg/L) 14.4 ± 3.7 12.6 ± 3.2 0.108 
    
Data are given as means with standard deviation. * Tested with t-test for independent 
samples. 
 
Mean s-ЕCP concentrations were higher in 
subjects of EG2 compared to those of CG, but 
statistical significance is not yet reached (Table 4). 
Table 4: Mean ECP serum concentrations in subjects of EG2 
and CG 
 EG2 
(n = 32) 
CG  
(n = 15) 
P-value* 
    
s-ECP (µg/L) 13.9 ± 3.5 12.6 ± 3.2 0.229 
    
Data are given as means with standard deviation.* Tested with t-test for independent 
samples. 
 
Table 5 shows the mean s-ECP 
concentrations in subjects of EG1 with exposure 
duration less or equal to 20 years and over 20 years.  
Table 5: Mean ЕCP serum concentrations in subjects of EG1 
according to job exposure duration 
 
 Exposed > 20 years 
(n = 24) 
Exposed ≤ 20 years   
(n = 11) 
P-value* 
    
s-ECP (µg/L) 16.2 ± 4.3 13.1 ± 3.1 0.039 
    
Data are given as means with standard deviation.* Tested with t-test for independent 
samples. 
 
Mean s-ЕCP concentrations were significantly 
higher in subjects of EG1 exposed more than 20 
years, compared to those with job exposure less than 
20 years.  
Table 6 gives an overview of mean s-ECP 
concentrations in subjects of EG2 with duration of 
exposure less or equal to 20 years and over 20 years.   
Table 6: Mean s-ECP concentrations in subjects of EG2 
according to job exposure duration  
 Exposed > 20 years 
(n = 22) 
Exposed ≤ 20 years   
(n = 10) 
P-value* 
    
s-ECP (µg/L) 15.1 ± 3.9 12.6 ± 3.2 0.086 
    
Data are given as means with standard deviation.* Tested with t-test for independent 
samples. 
 
Mean s-ECP concentrations were higher in 
subjects of EG2 exposed longer than 20 years 
compared to those with a shorter period of job 
exposure but without statistical significance.  
The mean s-ECP concentrations in subjects 
of all 3 groups depending on the smoking habit are 
given in Table 7. 
Table 7: Mean s-ECP concentrations in subjects of EG1, EG2, 
and CG depending on smoking habit 
Variable 
EG1  
(n = 35) 
P* 
EG2  
(n = 32) 
P* 
CG  
(n = 15) 
P* 
 21 vs 14  19 vs 13  9 vs 6  
s-ECP in active 
smokers 
s-ECP in non-
smokers 
15.5±4.1 
 
13.8±3.4 
0.208 
14.9±3.8 
 
12.7±3.5 
0.107 
13.7±3.6 
 
12.9±3.1 
0.664 
Data are given as means with standard deviation.* Tested with t-test for independent 
samples. 
 
The mean s-ECP concentrations were higher 
in smokers within the three groups, but without 
significant difference between smokers and non-
smokers.   
Mean s-ECP concentrations in all three 
groups due to the presence or absence of asthma are 
shown in Table 8. 
Table 8: Mean s-ECP concentrations in subjects of EG1, EG2, 
and CG due to the presence or absence of asthma 
  
Variable 
EG1  
(n = 35) 
P* 
EG2  
(n = 32) 
P* 
CG  
(n = 15) 
P* 
 7 vs 28  6 vs. 26  4 vs. 11  
s-ECP in subjects with 
asthma 
s-ECP in subjects 
without asthma 
18.9 ± 7.5 
 
13.6 ± 3.8 
0.013 
17.2 ± 6.9 
 
12.9 ± 3.7 
0 .039 
16.8 ± 4.9 
 
12.1 ± 3.2 
0.046 
       
Data are given as means with standard deviation. * Tested with t-test for independent 
samples. 
 
The mean s-ECP concentrations were 
significantly higher in subjects with asthma compared 
to non-asthmatics in all three groups. 
 
 
Discussion 
 
The average s-ECP concentrations were 
higher in subjects within EG1 and EG2 compared to 
those in CG, but without statistical significance. The 
average s-ECP concentrations were significantly 
higher among subjects in EG1 exposed more than 20 
years, compared to those with exposure less than 20 
years, while average s-ECP concentrations were non-
significantly higher in subjects of EG2 exposed more 
than 20 years, compared to those exposed less than 
20 years. The average s-ECP concentrations were 
higher among smokers within all three groups, but 
without reaching statistical significance between 
smokers and non-smokers, whereas they were 
significantly higher in asthmatic subjects compared to 
those without asthma in all three groups. Similar 
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results were obtained in the study of Heldal et al. [25] 
dedicated to occupational exposure to bio-aerosols 
while ECP as a marker of chronic airway inflammation 
was confirmed in the research conducted by Hamed 
et al. focused on the it’s predictive value in subjects 
with poorly controlled asthma and therapeutic 
response to inhaled corticosteroids [26].  
Substantial research work has been carried 
out to determine changes in s-ECP levels due to 
different allergic and non-allergic diseases over the 
last decades and especially during last two decades. 
As a result of these studies, enough quality work is 
now available to bridge the link between eosinophil 
activity and allergy phenomenon. Serum ECP is now 
closer to be declared as an established marker of 
allergy [27]. Many reported studies demonstrate an 
increase in s-ECP concentrations in asthmatic 
patients as compared to healthy controls [28][29]. 
Amongst the notable studies of eosinophil activity 
markers in induced sputum two studies found that 
ECP levels were significantly positively correlated with 
the mean weekly total symptom scores [30].  
The concentration of serum ECP has recently 
been found to correlate with ECP concentration in 
bronchoalveolar lavage fluid (BALF) [31]. Therefore, 
assessment of s-ECP may be considered to reflect 
pulmonary inflammation in asthma [32]. Studies of 
asthmatic patients, especially adults, have indicated a 
relationship between the level of serum ECP and the 
severity and nature of the disease [33][34]. The 
present study showed that the s-ECP levels were 
significantly elevated in asthmatic subjects as 
compared to that of healthy controls. This indicated 
the role of eosinophilic inflammation in the 
pathogenesis of asthma. It is clear that our results 
were consistent with previous studies that have shown 
that higher ECP levels in the serum of asthmatic 
patients when compared with healthy subjects [33] 
[34] [35]. Measuring of s-ECP levels have the 
advantages over eosinophilic count in that it reflects 
not only the number of cells but also their degree of 
activation and is, therefore, a better inflammatory 
marker [35]. The present study results show 
significant higher s-ECP levels in asthmatic subjects 
than those without asthma, regardless of the 
occupational exposure to respiratory hazards. Other 
studies [29] [34] [36] reported the same association 
between s-ECP levels and asthma severity. 
Thus assessment of s-ECP may be a 
reflection of pulmonary inflammation in bronchial 
asthma [37]. The presence of eosinophilic 
inflammation seems to be of importance since this 
feature is inconsistently observed in non-asthmatic 
atopic patients and absent in patients with a chronic 
cough [38]. Furthermore, these results indicate that 
although eosinophils are recruited in intermittent 
asthma, they are less activated in persistent asthma. 
The different patterns of eosinophilic activation found 
in persistent as compared with intermittent asthma 
might be important consequences of the integrity of 
the bronchial mucosa [39]. 
Direct measurement of airways inflammation 
using biological markers could potentially refine 
asthma management. This explains the current 
research interest in measuring levels of exhaled nitric 
oxide and eosinophil granule proteins especially s-
ECP in asthma [40]. The study by Zedan et al. [41] 
revealed that both peripheral eosinophil count and s -
ECP levels were significantly higher in atopic 
asthmatics as a group than in healthy control subjects. 
On the other hand, both parameters were significantly 
higher among partially controlled asthma cases 
compared with healthy control children as well as 
controlled asthma cases. Interestingly, however, 
controlled asthma cases showed non-significant 
changes in the levels of both parameters versus 
healthy control children. This finding is supported by 
the evidence that eosinophils play an important role in 
the pathogenesis of asthma and that elevation of 
peripheral blood eosinophil count is a risk factor for 
the development of airway remodelling and 
irreversible changes in lung function [42]. This is also 
supported by the research of Lee et al. who reported 
that higher levels of s-ECP were associated with more 
severe exacerbation of asthma followed by a 
decrease in s-ECP levels with a resolution of 
symptoms [43].  
Zedan et al. also showed a significant inverse 
correlation between the level of asthma control and 
both parameters, particularly s-ECP, implying that 
poorer control is expected with higher s-ECP levels 
[41]. This will add to the work of Koh et al., who 
described a correlation between asthma severity and 
s-ECP level. Thus, considering that s-ECP has been 
widely investigated as a potential biomarker of airway 
inflammation, it may have a useful role to play as a 
control parameter in asthma guidelines [2]. Mean s-
ECP values were significantly higher in cases of 
current allergic asthma than in non-allergic asthma, 
and lowest in non-asthmatic, non-atopic controls. In 
atopic asthmatics, ECP showed significant 
associations with airway obstruction and numbers of 
RAST allergens positive, as well as specific allergies, 
e.g. to swine and D. pteronyssinus [44]. Serum ECP is 
not a discriminating test for identifying asthma in 
epidemiology but can be used as a supplement to 
questionnaires and spirometry to indicate current 
asthma activity [42]. 
The results of a recent study in our country 
showed that the ICS objectively suppress the 
inflammatory reaction in asthma and the biologic 
markers (IL-5, Eo and s-ECP), which if being followed, 
can measure the accomplished effect. Therefore, they 
could be used in everyday practice, not only as 
diagnostic parameters but also as valid therapeutic 
guides in the treatment of asthma [45]. Another similar 
research showed that eosinophils, s -ECP and IL-5 
could be useful markers for selecting allergic patients 
and could be the monitors of treatment effects [46].  
Assessing eosinophilic inflammation is therefore 
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important in establishing a diagnosis, in monitoring 
and assessing response to treatment, and in testing 
novel therapeutics. Clinical markers of atopy and 
eosinophilic inflammation include indirect tests such 
as lung function, exhaled breath condensate analysis, 
fractional exhaled nitric oxide, serum immunoglobulin 
E levels and serum periostin. Direct measures, which 
quantify but do not anatomically localise inflammation, 
include blood eosinophil counts, serum or 
plasma eosinophil cationic protein and sputum 
eosinophil levels. Cytology from bronchoalveolar 
lavage and histology from endobronchial and 
transbronchial biopsies are better at localising 
inflammation but are more invasive. Novel 
approaches using radiolabelled eosinophils with 
single-photon emission computed tomography offer 
the prospect of non-invasive methods to localise 
eosinophilic inflammation [47]. 
Our present study has some limitations. 
Namely, relatively small number of the subjects in the 
study groups may be a limitation, with possible 
implications on the data obtained and its 
interpretation, especially having in mind their 
extrapolation on the population level for the 
agricultural workers in the Republic of Macedonia. 
Тhere is a lack of ambient monitoring and exposure 
measurement (endotoxin, dust, gases, vapours, and 
chemicals) in this survey. On the other hand, the data 
concerning exposure to respiratory hazards are based 
on job exposure matrices, introduced in our country.  
Finally, we can confirm that s-ECP is an important 
biomarker of airway inflammation present among 
farmers with asthma in means of reflecting disease 
severity and its prognosis. Furthermore, s -ECP levels 
were raised independently of smoking status in 
asthmatic subjects showing that s-ECP rise was a 
result of the inflammatory nature of the disease itself. 
In conclusion, despite the small sample size, 
this study has demonstrated that s-ECP may have 
clinical usefulness in assessing levels of asthma 
control and hence in refining asthma management. 
Based on these findings, our recommendation is 
conduction of a larger, randomized controlled trial to 
evaluate the correlation between s-ECP level and 
degree of asthma control, in order to obtain a cut-off 
point for s-ECP beyond which farmers with asthma 
may be considered uncontrolled, and to extrapolate 
this point on the population level among agricultural 
workers, having in mind exposure duration and its 
characteristics in farming, as well. 
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